N
BMRN icon

Nuveen’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nuveen’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-59,200
Closed -$5K – 3369
2020
Q4 		$5K Buy
+59,200
New +$4.69M ﹤0.01% 3265

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's BMRN Position: Q1 2026 in Review

Nuveen increased its BioMarin Pharmaceuticals (BMRN) stake by 3.8% in Q1 2026, buying an estimated $1.49M and bringing the position to 705,198 shares worth $39.8M. The position accounts for 0.01% of the portfolio, ranked #755.

Nuveen first reported a position in BMRN in Q2 2013 and has held it in 42 quarters since. The position peaked at $381M in Q2 2020. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Nuveen held 705,198 shares of BioMarin Pharmaceuticals worth $39.8M as of Q1 2026.
  • Nuveen bought 25,549 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.49M.
  • BioMarin Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q1 2026, its #755 holding.
  • Nuveen first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Nuveen's BioMarin Pharmaceuticals position peaked at $381M in Q2 2020.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.